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In some clinical trials conducted in the West, anti-
bodies against epidermal growth factor receptor 
（EGFR）, e.g., cetuximab and panitumumab, have been 
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???????
The use of antibodies against epidermal growth factor receptor （EGFR） in conjunction with conventional 
chemotherapy for metastatic colorectal cancer （CRC） in patients with KRAS wild-type tumors has been 
proven to be efficacious. Recently, KRAS testing prior to anti-EGFR therapy has become mandatory for 
metastatic CRC patients. Although newly developed pyrosequencing is expected to be one of the high 
throughput procedures detecting such mutations, the accuracy of the procedure has not been well evaluat-
ed. In the present study, we aimed to validate the accuracy, especially the potential for a false-negative re-
sult, in detecting KRAS mutations by pyrosequencing using cultured tumor cells. DNA extracted from cul-
tured ìNOZî gallbladder cancer cells （known to contain KRAS mutation G12V） at concentrations of 1％, 5％
, 10％, and 25％, as well as 2 DNA samples extracted from a resected CRC specimen （known to contain an-
other KRAS mutation, G12C） at concentrations of 5％ and 25％, were prepared. We analyzed KRAS muta-
tional status and nonexistent and/or nonfunctional mutations of these 6 samples using pyrosequencing. The 
KRAS mutation detection rates in the 4 NOZ samples （1％, 5％, 10％, and 25％） were 0.37％, 2.79％, 5.28％, 
and 13.85％, respectively. Some artifacts of KRAS mutations unlikely to be present were detected in 1％ 
samples of NOZ at a rate similar to that of the G12V mutation （G12C, 0.29％；G13C, 0.42％）. Although the 
KRAS mutation G12C was detected at rates of 1.26％ and 6.49％ in samples with 5％ and 25％ DNA ex-
tracted from resected CRC specimen, respectively, no other type of KRAS mutation was detected in such 
samples. Pyrosequencing could not detect KRAS mutations correctly in the sample containing 1％ DNA. 
This might cause false negatives. A sample mutated DNA concentration of at least 5％ was necessary for 
precise analyses by this procedure.
???? ????： KRAS mutation, pyrosequencing, colorectal cancer
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KRAS mutation screening with reportedly high sensi-
tivity and high throughput. To date, however, false-
negative results of pyrosequencing have not been re-
ported when detecting such mutations.  The minimum 
volume of specimen needed to detect a positive result 
correctly is not known. Therefore, the aim of the pres-
ent study using cultured tumor cells of the cell line 
NOZ was to evaluate the volume of specimen neces-
sary for the correct detection of KRAS mutations by 
pyrosequencing.
?????????????????????
Sample preparation
NOZ, a cultured gallbladder cancer cell line known 
to contain a KRAS G12V mutation, and HeLa, a cul-
tured cervical cancer cell line known to contain no 
KRAS mutation, were used for the present study. To 
determine the minimum DNA concentration for the 
correct detection of such mutations, DNA extracted 
from NOZ cells was admixed with DNA from HeLa 
cells to produce mixtures containing mutant DNA at 
concentrations of 1％ （sample 1）, 5％ （sample 2）, 10％ 
（sample 3）, and 25％ （sample 4） （Table 1）. Further-
more, we prepared surgically resected colon cancer 
specimens, the cells of which were known to contain 
the KRAS G12C mutation. Then, DNA extracted from 
the tumor tissue was admixed with DNA from non-tu-
mor cells of the same specimen to produce mixtures 
containing mutant DNA at concentrations of 5％ （sam-
ple 5） and 25％ （sample 6） （Table 1）. 
Mutation detection using pyrosequencing
Five hundred nanograms of each sample was pre-
pared and sent to a commissioned company （Roche 
shown to improve the efficacy of conventional chemo-
therapy regimens and have proven to be efficacious in 
conjunction with such regimens used in the initial 
treatment of metastatic colorectal cancer （CRC）, espe-
cially in patients with KRAS wild-type disease1〜4）. 
However, several studies have indicated that the pres-
ence of mutant KRAS in metastatic CRC is associated 
with a lack of response to anti-EGFR antibodies and 
correlates with a poor prognosis. Mutations in KRAS 
are found in approximately 40％ of CRCs, regardless of 
staging1,3 , 5〜7）. Circumventing ineffective anti-EGFR 
therapy in CRC patients with such mutations can 
avoid unnecessary adverse events, short survival time, 
and increased medical costs. Prior to treatment with 
anti-EGFR antibodies in metastatic CRC, KRAS test-
ing has become mandatory in the European Union and 
is recommended in the United States. However, to 
date, no specific procedure has been recommended to 
analyze KRAS mutations. Direct sequencing and al-
lele-specific polymerase chain reaction （PCR） assay 
are commonly used for such mutation analysis；how-
ever, direct sequencing requires high tumor cell per-
centages and good quality material, and sometimes ef-
fects an artifact in which some nonspecific mutations 
are detected due to poor quality of formalin fixation8,9）. 
Allele-specific PCR assay is a costly procedure and 
sometimes derives a false-positive result due to its 
sensitive detection. Therefore, screening assays that 
are accurate and efficient at low specimen volume and 
cost-effective with high throughput are required for 
the detection of KRAS mutations. Pyrosequencing is a 
real-time quantitative bioluminescence technique for 
the detection of short stretches of nucleic acid se-
quences. It is also a promising technology available for 
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???????　Sample compositions （DNA concentration；％）
Sample 1 2 3 4 5 6
NOZa 1 5 10 25 ─ ─
HeLab 99 95 90 75 ─ ─
Colon cancer 
cellsc
─ ─ ─ ─ 5 25
Non-tumor cells ─ ─ ─ ─ 95 75
aNOZ is known to contain the KRAS G12V mutation. bHeLa is known to 
contain no KRAS mutation.
cColon cancer cells from tissue of resected specimen are known to 
contain the KRAS G12C mutation.
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mutations were also detected with levels similar to 
that of G12V in sample 1 （Table 2）. KRAS mutation 
analysis using resected CRC specimens demonstrated 
that the detection rates of the G12C mutation of the 
lower concentration sample （5％；sample 5） and high-
er concentration sample （25％；sample 6） were 1.26％ 
and 6.49％, respectively （Table 2）. In sample 2, 4 non-
existent and/or nonfunctional point mutations were 
detected at a rate of more than 5％. One nonexistent 
point mutation （49；A＞T） was detected in all sam-
ples at a rate of more than 7％ （Table 2）. 
??????????
This is a fundamental investigation of the detection 
capability of KRAS mutations by pyrosequencing eval-
uated using DNA of the NOZ cell line in varying con-
centrations. We concluded that it was impossible to de-
tect specific KRAS mutations for identification at a 
sample mutated DNA concentration of 1％；therefore, 
a mutated DNA concentration of at least 5％ was nec-
essary to detect KRAS mutations correctly. However, 
a sample mutated DNA concentration of 5％ was suffi-
cient to detect such a mutation on the basis of results 
of the evaluation conducted using resected CRC speci-
Diagnostics Japan, Tokyo, Japan） for pyrosequencing. 
Pyrosequencing analysis of these 6 samples was per-
formed according to the manufacturer’s recommenda-
tions for the commercially available GS Junior Version 
2 .5 system （Roche Diagnostics Japan, Tokyo, Japan） 
with the GS Amplicon Variant Analyzer. Three KRAS 
mutations, including 2 involving codon 12 （G12V and 
G12C） and 1 involving codon 13 （G13C）, were target-
ed for analysis, in addition to 14 nonexistent and/or 
nonfunctional point mutations on another codons of 
KRAS. The authors were blinded to the procedure fol-
lowed by the company, and the company did not ob-
tain information about composition of these samples ei-
ther. After analysis for mutational status, we received 
the data from the company and identified the samples.
???????
Pyrosequencing was successfully performed in all 6 
samples. KRAS mutation analysis using NOZ DNA of 
varying concentrations （samples 1 to 4） revealed 
G12V mutation detection rates as 0.37％, 2.79％, 5.28
％, and 13.85％ （Table 2）. The detection rate of this 
mutation increased with increasing concentrations. 
However, theoretically nonexistent G12C and G13C 
??（1） （2013） 57
???????　Mutation detection rate by pyrosequencing
Sample 1 2 3 4 5 6
Nucleotide
numbera
Mutation
type
Variant
Detection
rate （％）
Number
of reads
Detection
rate （％）
Number
of reads
Detection
rate （％）
Number
of reads
Detection
rate （％）
Number
of reads
Detection
rate （％）
Number
of reads
Detection
rate （％）
Number
of reads
34 G＞T G12C 0.29 8,738 0.01 21,280 0 8,499 0.22 17,439 1.26 16,299 6.49 13,474
35 G＞T G12V 0.37 8,811 2.79 21,470 5.28 8,575 13.85 17,586 0.04 16,405 0 13,610
37 G＞T G13C 0.42 8,811 0.01 21,470 0.27 8,575 0 17,591 0 16,405 0 13,610
43 G＞T 0.2 8,836 5.46 22,804 0 8,596 0.34 17,604 0 16,492 0 13,611
44 G＞C 0 8,836 5.49 22,805 0 8,596 0.02 17,604 0 16,492 0 13,611
46 A＞C 1.06 8,872 6.66 22,946 0.88 8,607 0.84 17,872 0.94 16,511 1.01 13,626
47 A＞T 0 9,778 6.23 23,123 0 9,465 0 19,139 0 17,885 0 14,631
49 A＞T 11.13 9,944 7.1 23,126 9.63 9,489 8.27 19,185 8.36 18,017 7.16 14,655
60 G＞A 0.27 9,942 0 23,126 0.43 9,492 0.01 19,192 0 18,017 0.26 14,655
73 C＞A 1.53 9,930 0.44 23,121 0.87 9,520 0.76 19,190 0.01 18,021 0.04 14,652
75 G＞T 0.52 9,930 0.01 23,121 0.27 9,520 0.29 19,190 0 18,021 0.02 14,653
79 C＞A 1.31 9,930 0.39 23,120 1.08 9,520 0.72 19,180 0.04 18,021 0.04 14,652
82 T＞C 0.01 9,925 0.02 23,119 0 9,520 0.01 19,178 0.51 18,013 0 14,647
91 G＞T 1.15 9,902 0.45 23,111 0.75 9,509 0.69 19,178 0 18,012 0.07 14,640
97 G＞T 0.44 9,888 0.27 23,111 0.53 9,507 0.3 19,128 0 18,008 0 14,636
100 C＞A 0.81 9,873 0.26 23,095 0.5 9,474 0.4 19,131 0 18,008 0.05 14,626
136 T＞C 0 9,835 0 23,021 0.51 9,454 0.01 19,061 0.06 18,006 0.03 14,604
aNucleotide number indicates the number from initial nucleotide of initiating codon.
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considered useful for determination of the required 
minimal amount of sample. Furthermore, the credibili-
ty of such an analysis will be increased when samples 
remain anonymous, as in the present study. This fun-
damental evaluation will be important and helpful 
when findings of mutation detection differ between 
analyses using microdissected samples from tumors 
and samples without microdissection from resected 
specimens.
???????????
A mutated DNA concentration of at least 5％ was 
necessary to detect KRAS mutations correctly by py-
rosequencing.
????????????????????
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